These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8706451)

  • 1. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
    Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
    Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of nitric oxide in recombinant tumor necrosis factor-alpha-induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion.
    Zwaveling JH; Maring JK; Moshage H; van Ginkel RJ; Hoekstra HJ; Schraffordt Koops H; Donse IF; Girbes AR
    Crit Care Med; 1996 Nov; 24(11):1806-10. PubMed ID: 8917029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
    Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
    Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
    Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
    Hohenberger P; Latz E; Kettelhack C; Rezaei AH; Schumann R; Schlag PM
    Ann Surg Oncol; 2003 Jun; 10(5):562-8. PubMed ID: 12794024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan.
    Zwaveling JH; Hoekstra HJ; Maring JK; v Ginkel RJ; Schraffordt Koops H; Smit AJ; Girbes AR
    Nephron; 1997; 76(2):146-52. PubMed ID: 9200405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments.
    Sleijfer S; van Ginkel RJ; van der Mark TW; Hoekstra HJ; Zwaveling JH; Schraffordt Koops H; Mulder NH
    J Immunother; 1997 May; 20(3):202-7. PubMed ID: 9181458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs.
    Eggimann P; Chioléro R; Chassot PG; Lienard D; Gerain J; Lejeune F
    Chest; 1995 Apr; 107(4):1074-82. PubMed ID: 7705119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of continuous leakage monitoring with radioactive iodine-131-labeled human serum albumin during hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    van Ginkel RJ; Limburg PC; Piers DA; Koops HS; Hoekstra HJ
    Ann Surg Oncol; 2002 May; 9(4):355-63. PubMed ID: 11986187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of regional and systemic toxicity of isolated hyperthermic extremity perfusion with tumor necrosis factor-alpha and melphalan].
    Hohenberger P; Haier J; Kettelhack C; Schulze G; Schlag PM
    Chirurg; 1997 Sep; 68(9):914-20. PubMed ID: 9410682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response.
    Christoforidis D; Chassot PG; Mosimann F; Lienard D; Brunstein F; Bejko D; Lejeune FJ; Chiolero R
    Arch Surg; 2003 Jan; 138(1):17-25. PubMed ID: 12511144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
    Libutti SK; Barlett DL; Fraker DL; Alexander HR
    J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
    Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
    Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.